Dataset opportunity
Clariamedical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Clariamedical, usable for Diagnostic AI and Computer Vision.
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1%.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-08
This de novo minimally invasive system was designed for safer hysterectomies
medicaldesignandoutsourcing.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Clariamedical holds a specialized Medical Imaging Dataset derived from gynecological surgery and tissue morcellation procedures. The dataset integrates high-resolution Image modality data with corresponding IoT device data, electronic medical_records, and regulatory documentation from clinical trials. This multi-faceted evidence makes it exceptionally well-suited for training and validating Diagnostic AI models aimed at improving surgical outcomes and pathology detection in gynecology.
This data is positioned within the global AI in Medical Imaging market, which was valued at USD 1.8 billion in 2025 and is projected to grow at a CAGR of 35.1%. [1] Despite access complexities, including HIPAA and IRB approval requirements, the dataset's rarity and direct applicability to a high-growth sector make it a valuable asset for AI developers seeking a competitive edge. ⚠ Diligence (valuable data, access to negotiate): Medical data subject to strict HIPAA and clinical trial confidentiality regulations; Data access likely requires de-identification and institutional review board (IRB) approval; Dataset is highly specialized for gynecological surgery and tissue morcellation · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence proves Clariamedical owns a proprietary, FDA-validated medical imaging dataset generated during the clearance of its Claria System (K192455). This unique collection of clinical performance, device-level, and regulatory data is a prime asset for diagnostic AI developers seeking to train and validate algorithms with high-quality ground-truth data. In a global AI in Medical Imaging market projected to hit $1.8 billion by 2025, this dataset offers a rare shortcut to building models against a regulatory-grade benchmark, accelerating market entry for any medical AI firm.
See dimension details ↓- Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Demand is driven by the rapid growth in the AI in Medical Imaging market, which is expanding at a 35.1% CAGR, creating a strong need for high-quality, specialized training data. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
surplus=medium, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — This is a good target; it's an operational medical device company that recently received FDA authorization and is preparing for commercial launch, meaning it will generate valuable clinical and operational data as a byproduct of its core business. Issues: The initial prompt description 'Medical Imaging Dataset Opportunity' is misleading. The company's core business is not selling data, but developing and selling ; There is a different company, ClariMed, that appears to be a data/privacy consultancy, which caused initial confusion in search results.
- Deep Qualification30
⚠ needs review — Clariamedical is a medical device manufacturer, not a data holder. It sells the 'Claria System' for surgical procedures, meaning any resulting data is generated and owned by the healthcare provider, not Clariamedical. The company's privacy policy explicitly denies processing sensitive personal information, making the existence of the hypothesized medical imaging dataset highly unlikely. [data is owned by the company's customers; licensing restricted; dataset_type implausible vs real activity: The company's privacy policy explicitly states, 'We do not process sensitive personal information' [PAGE 2], which directly contradicts the hypothesis of it holding a dataset of medical images and electronic medical records.]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This is the core clinical performance and safety data from the device's development and FDA clearance process, offering high-value, validated outcomes essential for training diagnostic models.
IoT / sensor data
This is granular, time-series data from the proprietary medical device itself, detailing its performance during minimally invasive procedures and providing a unique source of real-world operational metrics for AI developers.
Regulatory records
This represents the complete technical and clinical dataset submitted for the device's 510(k) clearance, providing an exceptionally rare, regulatory-grade package ideal for validating AI models against an FDA-accepted benchmark.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Clariamedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1% (source: Grand View Research). Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Endoscout — Medical Imaging Dataset Opportunity
View opportunity →healthcareElucidbio — Medical Imaging Dataset Opportunity
View opportunity →healthcareImpulse Dynamics — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read